

The 3rd BioCentury-BayHelix

# EAST-WEST BIOPHARMA SUMMIT: SINGAPORE

*Organized by BioCentury and BayHelix  
in collaboration with McKinsey & Company*

**MAR**  
**4-6**  
**2024**

**SINGAPORE**

**MAR**  
**11-12**  
**2024**

**VIRTUAL**

As we head into 2024, biotechs are searching for ways to extend their runway and investors are seeking new portfolio companies and LPs. One solution: Tap into the emerging Asian markets.

With the growth of innovation in the East, including seemingly non-stop, cross-border deal flow, now is the time to meet with top executives and investors in Asia.

Join BioCentury, BayHelix and Insights Partner McKinsey & Company at the 3rd East-West Biopharma Summit in Singapore!

At the Summit, you will:

- Learn how the smart money pouring into Singapore will be deployed – both in Singapore and beyond.
- Meet key players from Asia's Innovation Arc, from India through Southeast Asia to China, Korea, and Japan.
- Discover emerging Asia biotechs looking for global partners and investors.
- Take home an exclusive conference report from McKinsey & Company on the rise of life sciences innovation in Asia.



**PARKROYAL COLLECTION MARINA BAY**

Organized by:

**BIOCENTURY**

**BayHelix**  
G R O U P

In collaboration with:

**McKinsey  
& Company**



## THANK YOU TO OUR ORGANIZING COMMITTEE



**ANDRÉ ANDONIAN**  
Chair of Asia Pacific and Strategic Advisor  
Flagship Pioneering




**JOSHUA BERLIN**  
Head of Business Development  
BioCentury Inc.



**KAREN BERNSTEIN, PH.D.**  
Co-Founder & Chairman  
BioCentury Inc.




**CHRISTINE BRENNAN**  
Managing Director  
Vertex Ventures HC



**IRENE CHONG**  
Executive Director, Innovation & Enterprise; A\*STAR Acting CEO, DxD Hub



**WAI CHIEW CHIK**  
Executive Director & CEO  
Heritas Capital Management




**VISHAL DOSHI**  
Chairman & CEO  
AUM Biosciences



**CARL FIRTH, PH.D.**  
Founder & CEO  
ASLAN Pharmaceuticals



**SIMONE FISHBURN, PH.D.**  
VP & Editor in Chief  
BioCentury Inc.



**DAVID FLORES**  
Co-Founder, President & CEO  
BioCentury Inc.



**PIERS INGRAM, PH.D.**  
Co-Founder & CEO  
Hummingbird Bioscience




**FRANCK LE DEU**  
Senior Partner & Co-Leader of  
Asia Life Sciences Practice  
McKinsey & Company



**CAROLYN NG, PH.D.**  
Partner & Managing Director  
TPG



**JOLENE OOI, PH.D.**  
Senior Principal  
EDBI



**ART PAPPAS**  
Managing Partner  
Pappas Capital



**AMY SCHULMAN**  
Managing Partner  
Polaris Partners



**VICTOR SHI, PH.D.**  
former BayHelix Chairman; Managing Partner  
Serica Partners



**JOAN SHEN, M.D., PH.D.**  
Founder & CEO  
NeuShen Therapeutics



**KHOO SHIH, PH.D.**  
CEO  
ClavystBio



**STEVE YANG, PH.D.**  
Co-CEO  
WuXi AppTec



**GUO-LIANG YU, PH.D.**  
former Chairman,  
BayHelix; Chairman & CEO  
Apollomics Inc.



**ANDREAS WALLNOEFFER, PH.D.**  
Partner  
Jeito Capital



**DAN ZHANG, M.D.**  
Co-Chairman  
Hillgene Biopharma



**Research, Partner, Connect — Starting Feb. 19, 2024**

Beginning Feb. 19, 2024, access to two important online portals within your event toolbox becomes available to assist you in making the most out of your event experience

Begin Scheduling  
1x1 Meetings

[biocenturyeastwest2024.meeting-mojo.com](https://biocenturyeastwest2024.meeting-mojo.com)

Log in with the credentials that will be emailed to you within 24 hours of registering and complete your attendee profile; then, on Feb. 19, 2024, take advantage of the opportunity to begin networking well ahead of this year’s event.

Search attendee profiles, send invitations, and book out meeting space to meet with potential partners. Don’t forget this year’s two bonus days of digital 1x1 meetings March 11-12, 2024.

**BioCentury’s Business Intelligence Platform**

provides access to pipelines, financings, and deals to help you better prepare for your 1x1 meetings.

Want to learn more? Schedule an online session with BioCentury for tips on how to use BCIQ at the East-West Summit:

[eastwestsummit@biocentury.com](mailto:eastwestsummit@biocentury.com)



The 3rd BioCentury-BayHelix

# EAST-WEST BIOPHARMA SUMMIT: SINGAPORE

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



BioCenturyEastWest.com

SINGAPORE

MAR

4-6

2024

VIRTUAL

MAR

11-12

2024

## INITIAL PRESENTING COMPANY CLASS OF 2024



上海跃赛生物科技有限公司  
SHANGHAI UniCell BIOTECHNOLOGY CO.,LTD





## PRESENTING COMPANY SCHEDULE

TUESDAY, MARCH 5, 2025	WEDNESDAY, MARCH 6, 2025
<b>CELL &amp; GENE THERAPY</b>	<b>AI-GUIDED DRUG DISCOVERY</b>
10:00 AM Exegensis Bio Inc.	9:00 AM Insilico Medicine Inc.
10:15 AM ImmunoScape Pte. Ltd.	9:15 AM Auransa Inc.
10:30 AM Nanjing Zillion Biotechnology Co. Ltd.	9:30 AM BluMaiden BioSciences Pte. Ltd.
10:45 AM Tikva Allocell Pte. Ltd.	9:45 AM MindRank Ltd.
11:00 AM Nuevocor Pte. Ltd.	<b>CANCER &amp; AUTOIMMUNE</b>
11:15 AM Medigene AG	10:00 AM GenFleet Therapeutics (Shanghai) Co. Ltd.
11:30 AM Genefab LLC	10:15 AM Hummingbird Bioscience Pte. Ltd.
11:45 AM Viralgen Vector Core S.L.	10:30 AM Albatroz Therapeutics Pte. Ltd.
12:00 PM Elpis Biopharmaceuticals Corp.	<b>DIAGNOSTICS</b>
<b>CANCER</b>	10:45 AM Sunbird Bio Inc.
1:30 PM B7 Therapeutics Inc.	11:00 AM RetiMark Co. Ltd.
1:45 PM Invion Ltd.	11:15 AM Qritive
2:00 PM Apollomics Inc.	11:30 PM Micronbrane Medical Co. Ltd.
2:15 PM Coherent Biopharma Co. Ltd.	<b>CARDIOVASCULAR, RESPIRATORY AND METABOLIC</b>
2:30 PM GeneMedicine Co. Ltd.	11:45 AM Nuance Pharma (Shanghai) Co. Ltd.
2:45 PM Geneos Therapeutics Inc.	12:00 PM Hua Medicine (Shanghai) Co. Ltd.
3:00 PM VerImmune Inc.	12:15 PM Pulnovo Medical
3:15 PM Sibylla Biotech S.p.A.	<b>HOT TOPICS</b>
3:30 PM PairX Bio Pte. Ltd.	12:30 PM Respiree Pte Ltd.
<b>NEUROLOGY, OPHTHALMIC AND OTOLOGIC</b>	12:45 PM Rejuveron Life Sciences AG
3:45 PM PurMinds Holdings Inc.	
4:00 PM Zhaoke Ophthalmology Ltd.	
4:15 PM Acousia Therapeutics GmbH	
<b>HOT TOPICS</b>	
4:30 PM Yunovia Co. Ltd.	
4:45 PM ChemLex Ltd.	
5:00 PM PPD Inc.	
5:15 PM Paratus Sciences Corp.	

**WHO YOU WILL MEET AT THE EAST-WEST BIOPHARMA SUMMIT***\* Preliminary list of select attending organizations*

AbAsia BioLabs Pte Ltd	Coherent Biopharma	JV Ventures
Abbisko Therapeutics	Collaborative Drug Discovery	KBio
AbbVie	Consortium for Clinical Research and Innovation Singapore	Leaps by Bayer
Accelerator Life Science Partners	Coulter Partners	Lerna Biopharma
Acousia Therapeutics	CoVBio	Lightstone Ventures
Adaptive Capital Partners	CR-CP Life Science Fund	LYFE Capital
Adel Nada Consultants, LLC	Davis Polk	McKinsey & Company
Adicon Clinical Laboratories	DotBio	Medigene AG
Advanced Cell Therapy and Research Institute	DROIA Ventures	Merck KGaA, Darmstadt, Germany
Agency for Science, Technology and Research (A*STAR)	DxD Hub	Mg BioPharma Consulting, LLC
Albatroz Therapeutics Pte Ltd	EDBI	Micronbrane Medical
Allay Therapeutics	Engine Bio	Milken Institute
AlphaLife Sciences	Exegensis Bio	MindRank Technologies Limited
Ananda Immunotherapies	Experimental Drug Development Centre (EDDC)	MiRXES
Apollomics, Inc.	Flagship Pioneering	Miz Partners Pte Ltd
ASLAN Pharmaceuticals Pte Ltd	Galimedix	Monograph Capital
August Global Partners	GeneFab	MPM BioImpact
AUM Biosciences	GeneMedicine	MSD/Merck
Auransa	Geneos Therapeutics, Inc.	NAH
B7 Therapeutics	GenFleet Therapeutics (Shanghai) Inc.	Nanjing Zillion Biotechnology Co. Ltd.
BayHelix Group	Guardant Health	Nanyang Technological University (NTU), Singapore
Become Consulting	Health Campus Limburg DC	National Research Foundation Singapore (NRF)
BeiGene	Heritas Capital Management	NeuShen Therapeutics
Biostate Pty Ltd	Hillgene	Novo Holdings Equity Asia
Biotheus	Hong Kong Biotechnology Organization	Novo Nordisk A/S
BluMaiden Biosciences	Hua Medicine	Novotech
Candel Therapeutics	Hummingbird Bioscience	NSG BioLabs
CBC Group	Hutchmed China Ltd.	NTUitive
Centenarian Fund	ImmunoScape Pte. Ltd.	Nuance Pharma
Chaperone VC	Insilico Medicine	Nuevocor Pte. Ltd.
ChemLex Ltd.	Invion Limited	OpenProtein.AI
Citigroup Global Markets Singapore Pte Ltd	IQT International Singapore	PairX Bio Pte. Ltd.
ClavystBio	IXP Lifesciences Pvt Ltd	Panacea Venture
co11ab@Novena	Jananom	Pappas Capital LLC
	Johnson & Johnson	Paratus Sciences

The 3rd BioCentury-BayHelix

# EAST-WEST BIOPHARMA SUMMIT: SINGAPORE

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



BioCenturyEastWest.com

SINGAPORE

MAR

4-6

2024

VIRTUAL

MAR

11-12

2024

## WHO YOU WILL MEET AT THE EAST-WEST BIOPHARMA SUMMIT

\* Preliminary list of select attending organizations

Pavilion Capital  
 Polaris Partners  
 PPD, part of Thermo Fisher  
 Pulnovo Medical  
 Pureos Bioventures  
 PurMinds NeuroPharma  
 Qiming Venture Partners  
 ReCerise Therapeutics  
 Rejuveron Life Science  
 RetiMark  
 REVIVO BioSystems Pte. Ltd.  
 Ring Therapeutics  
 Ropes & Gray

Russell Reynolds Associates  
 Rx Propellant  
 Sana Biotechnology  
 SCG Cell Therapy Pte Ltd  
 Serica Partners  
 SGINnovate  
 Shanghai Huaota Biopharmaceutical Co., Ltd  
 Sibylla Biotech  
 Sidley Austin LLP  
 Sunbird Bio, Inc.  
 Temasek International  
 Tikva Allocell

Twist Bioscience  
 Twogene Co., Ltd.  
 UniXell Biotechnology  
 VerImmune Inc  
 Vertex Growth  
 Vickers Venture Partners  
 Viralgen  
 VRise Therapeutics  
 Wacker Biotech  
 Yunovia  
 Zhaoke Ophthalmology  
 ZILLION BIO  
 Zymeworks

# 50+

PRESENTATIONS FROM CHINA, ASIA, THE WEST

ORGANIZED IN ROAD SHOW TRACKS

THE FUTURE LEADERS OF BIOTECH

# VETTED

SELECTED BY: BIOCENTURY & BAYHELIX



# ON-DEMAND

RECORDINGS AVAILABLE 24/7

BEFORE, DURING, AFTER REGARDLESS OF TIME ZONE

MEET WITH THE PRESENTING COMPANIES

# 1X1

MEETINGS

2 DAYS IN-PERSON, 2 DAYS VIRTUAL

The Presenting Company Class of 2023



**SCHEDULE-AT-A-GLANCE****\*\*This agenda is subject to change, for up to date information, please visit us online at: [BioCenturyEastWest.com](https://www.biocenturyeastwest.com)\*\*****MONDAY, MARCH 4, 2024**

11:00 AM — 4:00 PM	PRE-EVENT NETWORKING EXCURSIONS & LUNCH
6:00 PM — 6:30 PM	GENERAL REGISTRATION & NETWORKING
6:30 PM—6:40 PM	WELCOME & INTRODUCTIONS
6:40 PM—6:50 PM	WELCOME TO SINGAPORE
6:50 PM — 7:45 PM	BIOCENTURY SCENE SETTER: ASIA'S ARC OF INNOVATION
7:45 PM — 9:00 PM	NETWORKING WELCOME RECEPTION

**TUESDAY, MARCH 5, 2024**

8:00 AM — 9:00 AM	GENERAL REGISTRATION & NETWORKING BREAKFAST
8:00 AM — 9:00 AM	ADVANCING PRECISION ONCOLOGY: CEO NETWORKING BREAKFAST
9:00 AM — 5:30 PM	C—LEVEL PARTNERING MEETINGS – DAY 1
9:00 AM — 5:30 PM	POSTER SPOTLIGHT: TOP TRANSLATIONAL INNOVATION FROM SINGAPORE'S ACADEMICS
9:00 AM — 9:15 AM	OFFICIAL WELCOME FROM BIOCENTURY & BAYHELIX
9:15 AM — 10:00 AM	IS THIS THE ASIA MOMENT FOR BIOPHARMA INNOVATION?
10:00 AM — 5:30 PM	PRESENTING COMPANY PRESENTATIONS
10:00 AM — 10:45 AM	BUILDING PRODUCT ENGINES IN ASIA
10:45 AM — 11:15 AM	MORNING NETWORKING BREAK
11:15 AM — 12:00 PM	TALENT SHOWCASE: BUILDING BOARDS WITH GLOBAL VISION
12:00 PM — 1:30 PM	NETWORKING LUNCH: PEPPERMINT RESTAURANT
1:30 PM — 2:00 PM	FIRESIDE CHAT: ASIA'S ARC OF INNOVATION — THEN AND NOW
2:00 PM — 2:45 PM	R&D SHOWCASE #1: HOW WILL ASIA DRIVE BIOTECH'S GOLDEN AGE?

2:45 PM — 3:30 PM	R&D SHOWCASE #2: DIAGNOSTICS — BEYOND MARKET BOUNDARIES
3:30 PM — 4:00 PM	AFTERNOON NETWORKING BREAK
4:00 PM — 4:45 PM	R&D SHOWCASE #3: CAN ASIA TURN FDA'S MRCT REQUIREMENT TO A STRATEGIC ADVANTAGE?
4:45 PM — 5:30 PM	THE ROAD AHEAD FOR SINGAPORE
5:30 PM — 6:00 PM	FIRESIDE CHAT: TRAVELING THE LONG INNOVATION ROAD
6:00 PM — 7:30 PM	NETWORKING RECEPTION
6:30 PM— 7:30 PM	POSTER SPOTLIGHT PRESENTATIONS: AT THE FOREFRONT OF TRANSLATION INNOVATION
7:30 PM — 9:00 PM	NETWORKING DINNER

**WEDNESDAY, MARCH 6, 2024**

8:00 AM — 9:00 AM	GENERAL REGISTRATION & NETWORKING BREAKFAST
9:00 AM — 2:00 PM	C—LEVEL PARTNERING MEETINGS – DAY 2
9:00 AM — 2:00 PM	POSTER SPOTLIGHT: TOP TRANSLATIONAL INNOVATION FROM SINGAPORE'S ACADEMICS
9:00 AM — 9:45 AM	CAPITAL MARKETS SHOWCASE: THE BUYSIDE VIEW
9:00 AM — 12:00 PM	PRESENTING COMPANY TRACKS
9:45 AM — 10:30 AM	DEALMAKERS SHOWCASE: TAPPING ASIA'S INNOVATION
10:30 AM — 11:00 AM	MORNING NETWORKING BREAK
11:00 AM — 11:30 AM	DEALMAKERS CASE STUDY: MERCK KGAA & ABBISKO
11:30 AM — 12:15 PM	CEO & INVESTOR ROUNDTABLE: WHAT'S NEXT?
12:15 PM — 1:00 PM	CLOSING RAPPORTEUR PLENARY: MOBILIZING IN SINGAPORE AND ASIA
1:00 PM — 2:00 PM	NETWORKING LUNCH & CLOSING RECEPTION
2:30 PM — 5:00 PM	ECOSYSTEM TOUR & RECEPTION



The 3rd BioCentury-BayHelix

# EAST-WEST BIOPHARMA SUMMIT: SINGAPORE

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



BioCenturyEastWest.com

SINGAPORE

MAR

4-6

2024

VIRTUAL

MAR

11-12

2024



## Pre-Event Networking Excursion

### GIN, TONIC & THE EMPIRE TOUR

March 4, 2024 - 11am - 4pm Departing from the ParkRoyal

Join our experienced World War II guide as we take you back to the “empire,” to Labrador Park where gun emplacements, casemates, and machine gun pillboxes once stood to protect Singapore. Then head on over to the Brass Lion Distillery, where you continue the journey of learning about the gin distilling process, and how the distillery’s signature Singapore Dry Gin came about with 22 botanicals comprising traditional Asian flavors like torch ginger and lemongrass! The experience concludes with a tasting flight of three gins followed by lunch at the Arbora Hilltop Garden & Bistro.



*\*Space is limited and requires advance registration\**  
Email [conferences@biocentury.com](mailto:conferences@biocentury.com) for more information.



*\*\*This agenda is subject to change, for up to date information, please visit us online at: [BioCenturyEastWest.com](https://BioCenturyEastWest.com)\*\**

**MONDAY, MARCH 4, 2024**

- 11:00 AM — 4:00 PM      **PRE-EVENT NETWORKING EXCURSIONS & LUNCH**  
**EXCURSION 1: GIN, TONIC & THE EMPIRE TOUR**  
*Join our experienced World War II guide as he takes you back to the “empire”, to Labrador Park where gun emplacements, casemates, and machine gun pillboxes once stood to protect Singapore. Then head on over to the Brass Lion Distillery, where you continue the journey of learning about the gin distilling process, and how the distillery’s signature Singapore Dry Gin came about with 22 botanicals comprising of traditional Asian flavors like torch ginger and lemongrass! The experience concludes with a tasting flight of three gins followed by lunch at the Arbora Hilltop Garden & Bistro.*  
**\*Limited capacity, requires advance registration. Please contact [conferences@biocentury.com](mailto:conferences@biocentury.com) for additional information**
- 6:00 PM — 6:30 PM      **GENERAL REGISTRATION & NETWORKING**
- 6:30 PM— 6:40 PM      **WELCOME & INTRODUCTIONS**  
 Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury
- 6:40 PM— 6:50 PM      **WELCOME TO SINGAPORE**  
 Beh Kian Teik, CEO, Singapore National Research Foundation, and Chairman of Singapore's Biotech Working Committee
- 6:50 PM — 7:45 PM      **BIOCENTURY SCENE SETTER: ASIA’S ARC OF INNOVATION**  
*The word is out: Western investors, pharmas and biotechs are placing significant bets on globally competitive technologies arising in Asia. International capital is flowing to Singapore in search of opportunity. Mixing traditional and emerging strengths in new modality engineering, data science, genomics and biomanufacturing, Asia’s draw is clear. The question is how this Arc of Innovation will evolve. Setting the scene for the 3rd BioCentury-BayHelix East-West conference, this panel will discuss how the expanding East-West ecosystem can transform drug discovery and development.*
- Welcome:                Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury
- Session Chair:        André Andonian, Chair of Asia Pacific & Senior Advisor, Flagship Pioneering
- Panelists:                Mark Lotter, Founder & CEO, Nuance Biotech  
 Mario Pennisi, Managing Director, biostate  
 Amy Schulman, Managing Partner, Polaris Partners  
 Khoo Shih, Ph.D., CEO, ClavystBio  
 Tan Sze Wee, M.D., Assistant Chief Executive, Biomedical Research Council, A\*STAR
- 7:45 PM — 9:00 PM      **NETWORKING WELCOME RECEPTION**





**TUESDAY, MARCH 5, 2024**

- 8:00 AM — 9:00 AM GENERAL REGISTRATION & NETWORKING BREAKFAST
- 8:00 AM — 9:00 AM **ADVANCING PRECISION ONCOLOGY: CEO NETWORKING BREAKFAST**  
*Network with biopharma leaders and investors and discuss the future of cancer care. Discover how innovative next-generation sequencing (NGS) liquid biopsies are propelling precision oncology forward. Explore the potential of molecular insights derived from blood and tissue tests, guiding treatment decisions and revolutionizing cancer care. Space is limited; and reserved for senior-level executives and investors. Please email [conferences@biocentury.com](mailto:conferences@biocentury.com) for additional information.*  
Session chair: Simranjit Singh, CEO, Guardant Health Asia, Middle East & Africa (AMEA)  
**Hosted by: Guardant Health**
- 9:00 AM — 5:30 PM C—LEVEL PARTNERING MEETINGS – DAY 1
- 9:00 AM — 5:30 PM **POSTER SPOTLIGHT: AT THE FOREFRONT OF TRANSLATION INNOVATION**  
**Singapore's academics and East-West Presenting Companies describe translational breakthroughs with commercial potential in poster format**  
*The flow of translational innovations from Asia's academic centers is rising, making it more important than ever to connect top translational researchers with the networks required to turn discoveries into drugs. Likewise, innovative biotechs are pushing the frontiers of translational science. This poster session features innovators from Singapore's academic ecosystem whose early stage research has near-term commercial potential, alongside East-West Presenting Companies that have begun their journey. The posters provide deep dives into the scientific basis of the latest translational breakthroughs.*  
**Co-Hosted by: NSG Biolabs & NSG Ventures**
- 9:00 AM — 9:15 AM **OFFICIAL WELCOME FROM BIOCENTURY & BAYHELIX**  
 David Flores, CEO, BioCentury  
 Victor Shi, Ph.D., former Chairman, BayHelix, and Managing Partner, Serica Partners
- 9:15 AM — 10:00 AM **IS THIS THE ASIA MOMENT FOR BIOPHARMA INNOVATION?**  
*By 2030, across almost all demographics and economic metrics, Asia will be the new majority. But today, despite progress, Asia is punching below its weight in biopharma innovation. In its 3rd East-West Summit report, Insights Partner McKinsey & Company looks at opportunities and challenges across Asia's emerging Arc of Innovation, and asks where Asia biopharma will stand by 2030. Advanced access to McKinsey's report is available exclusively to East-West Summit delegates.*  
Session co-Chairs: Fangning Zhang, Partner, McKinsey & Company  
 Jay Park, Associate Partner, McKinsey & Company
- 10:00 AM — 5:30 PM PRESENTING COMPANY PRESENTATIONS
- 10:00 AM — 10:45 AM **BUILDING PRODUCT ENGINES IN ASIA**  
*With Singapore having laid the groundwork of its biotech ecosystem, its mission is to sustainably turn its core science into products that can attract international investors and partnerships. Across Asia's Arc of Innovation, likewise, globally-minded biotechs need to build product engines to go from preclinical proof of mechanism to Phase II proof of concept, and eventually to approval and commercial validation. But this path is challenging everywhere in the world. This session will examine how innovators in Singapore and across Asia can go about turning science and technology into products.*



Session Chair: Michael Stibilj, Chief Operating Officer, Novotech

Panelists: Vishal Doshi, Founder & CEO, AUM Biosciences  
 Dominik Escher, Ph.D., Managing Partner, Pureos Bioventures  
 Vishal Goel, Co-Founder, JV Venture  
 Piers Ingram, Ph.D., Co-Founder, CEO & Executive Director, Hummingbird Bioscience  
 Vijay Karwal, Operating Partner, CBC Group

10:45 AM — 11:15 AM **MORNING NETWORKING BREAK**

11:15 AM — 12:00 PM **TALENT SHOWCASE: BUILDING BOARDS WITH GLOBAL VISION**

*As biotechs scale up, their boards must evolve too. From managing global development programs to finding partners, biotech boards must help CEOs make increasingly tough decisions that require a global network and mindset. In the East-West Summit's 3rd Talent Showcase, biotech investors and CEOs discuss how to build a board to meet the challenges of today, and how to manage the board's evolution as a company scales and globalizes.*

Session Co-Chairs: Yvonne Lu, Co-Lead, Global Biopharma Practice, Russell Reynolds  
 Anupama Puranik, Managing Director, Russell Reynolds Associate

Panelists: Sharon Chan, DPhil, VP, Asia Pacific, JLABS, Johnson & Johnson  
 Luc Dochez, Pharm.D., Managing Partner, Droia Ventures  
 Ansbert Gadicke, M.D., Managing Partner, MPM Biolmpact  
 James Huang, Managing Partner, Panacea Venture

12:00 PM — 1:30 PM **NETWORKING LUNCH: PEPPERMINT RESTAURANT**

1:30 PM — 2:00 PM **FIRESIDE CHAT: ASIA'S ARC OF INNOVATION — THEN AND NOW**

*Art Pappas brings a long perspective on the Asian ecosystem, having served 23 years in MNC C-level roles with GSK, Abbott, and Dow Chemical before going on to his career as founder of Pappas Capital 30 years ago. In 2021, he launched Asian Innovation Ventures to invest in next-generation life science technologies from China and Singapore. His Pappas Translational Medicine initiative resides at the nexus where academic discovery science and the private sector combine to transform innovation to market-ready assets. In a fireside chat with BioCentury, Pappas shares his perspectives on the path forward for science, technology, and investment in Asia.*

Session Chair: David Flores, CEO, BioCentury

Panelists: Art Pappas, Managing Partner, Pappas Capital

2:00 PM — 2:45 PM **R&D SHOWCASE #1: HOW WILL ASIA DRIVE BIOTECH'S GOLDEN AGE?**

*Biotech has entered a golden age, with new frontiers in ADCs, bispecifics and cell therapies, new classes of small molecules, and an ever-expanding toolkit for delivering, disrupting and editing genes. What role are Asian innovators playing? Are they creating Hot Spots of innovation in specific technologies or disease areas? And where will Singapore leverage its greatest domain expertise? This panel will dive into the emerging strengths of Asia's biotech Hot Spots and the centers of excellence where Western R&D leaders and investors are looking to the region for innovation.*

Session Chair: Selina Koch, Ph.D., Executive Editor, BioCentury





**Panelists:** Alice Chen, Ph.D., EVP, Accelerator Life Science Partners  
 David Epstein, Ph.D., President & CEO, PairX Bio  
 Theresa Heah, M.D., CEO, Paratus Sciences  
 Qiang Lu, Ph.D., Co-Founder & Chairman, GenFleet Therapeutics  
 Choon-Peng Ng, CEO, ImmunoScape  
 Pei Sze Ng, Ph.D., Direct of Venture Investments, Leaps by Bayer

2:45 PM — 3:30 PM

**R&D SHOWCASE #2: DIAGNOSTICS — BEYOND MARKET BOUNDARIES**

*The East-West flow of innovation presents opportunities for Asian and Western diagnostics developers to expand beyond domestic markets to serve global patient needs. In doing so, one needs to navigate complex regional regulatory requirements as well as marketing channels. This session will analyze how diagnostics players can create global commercial scale, while anticipating how AI will create next-generation opportunities in both Asia and the West.*

**Session Chair:** Victor Shi, Ph.D., Managing Partner, Serica Partners

**Panelists:** Yang Chu, Partner, Davis Polk  
 Simranjit Singh, CEO, AMEA, Guardant Health  
 Ruifen Weng, Ph.D., Deputy CEO and Chief Technology Officer, DxD Hub  
 Larry Wang, CFO, Adicon Clinical Laboratories  
 Lihan Zhou, Ph.D., Co-Founder and CEO, MiRXES

3:30 PM — 4:00 PM

**AFTERNOON NETWORKING BREAK**

4:00 PM — 4:45 PM

**R&D SHOWCASE #3: CAN ASIA TURN FDA'S MRCT REQUIREMENT TO A STRATEGIC ADVANTAGE?**

*Multiregional clinical trials have taken on outside significance since FDA asserted their importance to regulatory decision-making, but cross-border differences in standard of care, regulatory flexibility and complexities of transferring data represent major obstacles for biotechs. At the same time, genomics and AI each offer new opportunities for finding the right patient population to match a drug's intended use. Can Asia's stakeholders marry the challenge and opportunity to solve for some of the biggest hurdles? This panel will discuss whether Asia can develop the infrastructure needed for MRCTs, and whether there are opportunities to create a competitive advantage by conducting trials in Asia.*

**Session Co-Chairs:** Joan Shen, M.D., Ph.D., CEO, Neushen Therapeutics

**Panelists:** Dan Zhang, M.D., Co-Chairman, Hillgene  
 Pek Lum, Ph.D., CEO, Auransa  
 Tuyen Ong, M.D., CEO, Ring Therapeutics, and CEO Partner, Flagship Pioneering  
 Michael Shi, Ph.D., EVP, Head of R&D and Chief Medical Officer, Hutchmed China Ltd.  
 Danny Soon, M.D., CEO, Consortium for Clinical Research and Innovation, Singapore, and Executive Director, Advanced Cell Therapy and Research Institute, Singapore  
 Albert Yu, Ph.D., Founder & Chairman, Hai Kang Life, and Chairman, Hong Kong Biotechnology Organization (HKBIO)



4:45 PM — 5:30 PM

**THE ROAD AHEAD FOR SINGAPORE**

*Singapore, already a hub for strong discovery science, has leapt onto the global biotech radar as a destination for professional international investors. The question is how this money and science will propel Singapore forward in the global biotech ecosystem. Will Singapore become a financial center that seeds and funds key players in Asia from concept to bellwether? Will it become a place where discovery science is translated into products with global impact? Or will it become a region that creates outstanding innovations that are developed elsewhere? This panel will discuss the paths ahead and what must happen for Singapore to maximize its impact for patients and investors worldwide.*

Session Chair: Carl Firth, Ph.D., CEO, ASLAN Pharmaceuticals

Panelists: Jui Lim, M.D., CEO, SGIInnovate

Basil Lui, Ph.D., Founding Partner; August Global Partners

Ken Noonan, Ph.D., Advisor, Lightstone Ventures

Damian O'Connell, Ph.D., CEO, Singapore Experimental Drug Development Centre (EDDC)

Daphne Teo, Founder and Managing Partner, NSG Ventures

5:30 PM — 6:00 PM

**FIRESIDE CHAT: TRAVELING THE LONG INNOVATION ROAD**

Douglas Williams has been managing innovation for decades, from the development of blockbusters such as Enbrel and Tecfidera to game-changing next-generation drugs such as Spinraza. He has run research groups large and small – as EVP of R&D at Immunex, CSO of Seattle Genetics and head of R&D at Biogen – and served as CEO at ZymoGenetics and Codiak BioSciences. And throughout, he's been at the forefront of solving the problems of new modality innovation, from mAbs to ADCs to antisense to exosomes, pioneering manufacturing solutions and carving regulatory paths. Today, he is using cell engineering to build a pipeline of products as head of R&D at Sana Biotechnology. In this Fireside Chat with BioCentury, Williams provides his lessons for navigating the path from discovery to the realization of new medicines.

Session Chair: Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury

Panelists: Douglas Williams, Ph.D., Head of Research and Development, Sana Biotechnology

6:00 PM—7:30 PM

**NETWORKING RECEPTION**

6:30 PM — 7:30 PM

**POSTER SPOTLIGHT PRESENTATIONS: AT THE FOREFRONT OF TRANSLATION INNOVATION**

**Singapore's academics and East-West Presenting Companies describe translational breakthroughs with commercial potential in poster format**

*The flow of translational innovations from Asia's academic centers is rising, making it more important than ever to connect top translational researchers with the networks required to turn discoveries into drugs. Likewise, innovative biotechs are pushing the frontiers of translational science. This poster session features innovators from Singapore's academic ecosystem whose early stage research has near-term commercial potential, alongside East-West Presenting Companies that have begun their journey. The posters provide deep dives into the scientific basis of the latest translational breakthroughs.*

Honorary Chairwoman: Daphne Teo, CEO of NSG Biolabs and NSG Ventures

**Co-Hosted by: NSG Biolabs & NSG Ventures**



7:30 PM — 9:00 PM **GALA NETWORKING DINNER**

**WEDNESDAY, MARCH 6, 2024**

8:00 AM — 9:00 AM GENERAL REGISTRATION & NETWORKING BREAKFAST

9:00 AM — 2:00 PM C—LEVEL PARTNERING MEETINGS – DAY 2

9:00 AM — 2:00 PM **POSTER SPOTLIGHT: AT THE FOREFRONT OF TRANSLATION INNOVATION**

**Singapore's academics and East-West Presenting Companies describe translational breakthroughs with commercial potential in poster format**

*The flow of translational innovations from Asia's academic centers is rising, making it more important than ever to connect top translational researchers with the networks required to turn discoveries into drugs. Likewise, innovative biotechs are pushing the frontiers of translational science. This poster session features innovators from Singapore's academic ecosystem whose early stage research has near-term commercial potential, alongside East-West Presenting Companies that have begun their journey. The posters provide deep dives into the scientific basis of the latest translational breakthroughs.*

**Co-Hosted by: NSG Biolabs & NSG Ventures**

9:00 AM — 9:45 AM **CAPITAL MARKETS SHOWCASE: THE BUYSIDE VIEW**

*Investor money has poured into Singapore. Western MNCs and biotechs are acquiring innovations from Asia at globally competitive prices. This unique panel assembles buy-side stakeholders to identify what is driving this ecosystem and what kinds of assets will drive investments and partnerships, both in Asia and for the world.*

**Session Chair:** Steve Wang, Ph.D., Partner, Davis Polk

**Panelists:** Wai Chiew Chik, CEO & Executive Director, Heritas Capital  
 Curtis Chin, Chair, Asia Fellows; Senior Advisor, Global Markets, Milken Institute  
 George Lin, EVP & Chief Strategy Officer, Hua Medicine  
 Jolene Ooi, Senior Principal, EDBI  
 Matthew Sheroff, Head of Business Development, Janssen Asia Pacific, J&J  
 Shelby Zhang, Ph.D., Director, Vertex Growth

9:00 AM — 12:00 PM PRESENTING COMPANY TRACKS

9:45 AM — 10:30 AM **DEALMAKERS SHOWCASE: TAPPING INTO ASIA'S INNOVATION**

*Western companies are in-licensing Asian innovation at a record pace. What are MNCs and Western biotechs looking for as they pursue partners and assets in Asia and how can Asian biotechs position themselves to find the best deal to maximize their growth? This panel of experienced dealmakers will explore how dealmaking is a strategic opportunity to build awareness of Asia's place among global innovators.*

**Session Chair:** Ruchun Ji, Partner, Sidley

**Panelists:** Jun Bao, Chief Business Officer, Biotheus  
 Lisa Feng, CFO and Chief Business Officer, Zhaoke Ophthalmology  
 Sridhar Mandapati, Head, International Business Development, AbbVie  
 Nikhil Mutyal, Ph.D., Executive Director, Business Development & Licensing, MSD/Merck & Co.  
 Chae Joon Lee, Chief Business Officer, Yunovia  
 Jenny Yang, Ph.D., Senior Director, Global Search & Evaluation, Novo Nordisk



10:30 AM — 11:00 AM

**MORNING NETWORKING BREAK**

11:00 AM — 11:30 AM

**DEALMAKERS CASE STUDY: MERCK KGAA & ABBISKO**

*The deal between Merck KGaA and Shanghai-based Abbisko tells the tale of the surge in East-West partnerships centered on innovative assets coming from Asia. Merck gained China rights to late-stage CSF1R antagonist pimicotinib, giving it access to a potentially first-in-class cancer therapy and the opportunity to expand its commercial footprint in oncology in China. This session delivers the inside story on the deal: how the agreement came together and what the partners see as keys to a successful cross-border partnership.*

Session Chair:

Panelists: Zhui Chen, Ph.D., Co-founder & Chief Scientific Officer, Abbisko Therapeutics  
Birgit Reitmaier, Ph.D., Executive Director & Head of BD Asia Pacific, Merck KGaA

11:30 AM — 12:15 PM

**CEO & INVESTOR ROUNDTABLE: WHAT'S NEXT?**

*In a special breakout session, Insights Partner McKinsey & Company gathers CEOs and investors to debate what comes next for biopharma innovation in Asia.*

Session Chair: Michele Ravicioni, Senior Partner & Head Asia Life Sciences, McKinsey & Company

Panelists: Kathy He, CEO, Lerna Biopharma  
Navjeevan Khosla, Partner, Novo Holdings Equity Asia

12:15 PM — 1:00 PM

**CLOSING RAPPORTEUR PLENARY: MOBILIZING IN SINGAPORE AND ASIA**

*Where does Asia's Arc of Innovation go from here? This closing rapporteur session identifies the key takeaway messages from the 3rd East-West Biopharma Summit.*

Session Co-Chairs: David Flores, CEO, BioCentury  
Victor Shi, Ph.D., former Chairman, BayHelix, and Managing Partner, Serica Partners

Panelists: Da Liu, Managing Director, CR-CP Life Science Fund  
Helen Lin, Executive Medical Director, JPAC, Amgen  
Jeffrey Lu, Co-Founder & CEO, Engine Biosciences  
Joanna Wang, General Counsel & Board Secretary, Insilico Medicine  
Fong Ming Koh, Investment Principal, LYFE Capital

1:00 PM — 2:00 PM

**NETWORKING LUNCH & CLOSING RECEPTION**

2:30 PM — 5:00 PM

**ECOSYSTEM TOUR & RECEPTION**

*Join BioCentury, BayHelix, and A\*Star for an exclusive tour of Biopolis, Singapore's biomedical R&D hub. Visit research institutes and meet local leaders for a final round of networking at the A\*Star reception. Transportation provided.*



The 3rd BioCentury-BayHelix

# EAST-WEST BIOPHARMA SUMMIT: SINGAPORE

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



BioCenturyEastWest.com

SINGAPORE

MAR

4-6

2024

VIRTUAL

MAR

11-12

2024

## BONUS CONTENT

BIOCENTURY



Join Jeff Cranmer, Executive Editor and host of “*BioCentury This Week*,” for this exclusive “East-West Biopharma Summit” preview episode:

### Week of February 26

East-West Biopharma Summit Preview

*BioCentury This Week* features in-depth conversations with BioCentury’s editorial team on current topics in biopharma. Past episodes are available on Apple Podcasts, Spotify, Google Podcasts, Overcast, Pocketcasts, Podcast Addict, Castbox, BeyondPod, Downcast, layerFM, Breaker, and RadioPublic.

## ECOSYSTEM TOUR & RECEPTION

Join BioCentury, BayHelix, and A\*Star for an exclusive tour of Biopolis, Singapore’s biomedical R&D hub. Choose to tour one of the following research institutes: (1) Experimental Drug Development Centre (EDDC), (2) Diagnostics Development Hub (DxD Hub), or (3) Nucleic Acid Therapeutics Initiative (NATi) / Bioprocessing Technology Institute (BTI), and meet local leaders for a final round of networking at the A\*Star reception. Transportation provided.

[CLICK HERE TO SIGN UP TODAY!](#)



March 6, 2024 - 2:30pm - 5:00pm

Departing from the ParkRoyal— *Transportation will be provided*



*\*Space is limited and requires advance registration\**

Email [conferences@biocentury.com](mailto:conferences@biocentury.com) for more information.

The 3rd BioCentury-BayHelix

# EAST-WEST BIOPHARMA SUMMIT: SINGAPORE

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



BioCenturyEastWest.com

SINGAPORE

MAR  
4-6  
2024

VIRTUAL

MAR  
11-12  
2024

# 24<sup>TH</sup> BIO€QUITY EUROPE

BIOEQUITYEUROPE.COM

# 2024

SAVE THE DATE

MAY 12-14 KURSAAL ELKARGUNEA CENTER  
**SAN SEBASTIÁN, SPAIN**

MAY 21-22 VIRTUAL 1x1 MEETINGS



ORGANIZED BY  
BIOCENTURY  
**EBD  
GROUP**

Celebrating its 24th year, Bio€quity Europe is the industry's premier international bio-tech showcase where connections are made, relationships are built, and opportunities are uncovered.

Join us May 12-14, 2024, in San Sebastián, Spain. This conference is designed exclusively for the C-Suite of financial dealmakers, biopharma executives, venture capitalists, private investors and policymakers.







## FAQs

### Who should attend?

- This C-suite conference is designed for financial dealmakers, biopharma executives, venture capitalists, private investors and policymakers.
- It is the place to network, partner and debate strategies for global development.
- It is the place to build trusted cross-border relationships.

### The program is tailored for:

- Biotechs seeking new partnerships in Asia
- Family Offices looking to be an LP for Western VCs
- Big Biopharmas exploring how Singapore is changing and moving towards innovation.

### Who will I meet?

Don't miss the opportunity to meet with VCs, CEOs, CFOs, CBOs, and decision-makers shaping the future of innovation – from both the East and West including executives from:

*A\*STAR, Accelerator Life Science Partners, Acousia Therapeutics, ASLAN Pharmaceuticals, AUM Biosciences, Auransa, B7 Therapeutics, Candel Therapeutics, CBC Group, Citi, ClavystBio, DotBio, EDBI, Exegenesis Bio, Flagship Pioneering, GeneMedicine, Heritas Capital, Hua Medicine, Hummingbird Biosciences, LYFE Capital, Medigene, MindRank Technologies, MSD, NAH, Novo Holdings, Nuevocor, Panacea Venture, Polaris Partners, Qiming Venture Partners, RetiMark, and Vertex Ventures among others.*

### What will I learn?

This year's Summit will include two-plus days of strategic panels on:

- Access to Capital & Partners in Asia
- Singapore as a Strategic Gateway
- Arc of Innovation in Asia

### When is the summit?

The East-West Biopharma Summit takes place March 4-6, 2024, at the ParkRoyal Collection in Marina Bay, Singapore.

Can't attend in person? There are also two bonus days of virtual partnering meetings, March 11-12, 2024.

### Why is the summit important?

For 11 years, BioCentury, BayHelix and Insights Partner McKinsey & Company have brought together a cross-border community of C-level executives and investors to network, partner and debate critical issues facing the global biotech industry.

In 2024, BioCentury and BayHelix bring the 3rd East-West Biopharma Summit to Singapore, where 20 years of government-led investment in science, talent and infrastructure has set the stage for the life sciences industry to carry the ball forward.

The East-West Biopharma Summit is THE forum to debate globalization strategies and form trusted cross-border relationships. There is no other strategic venue of this kind.

**Unparalleled networking and market access:** The Summit is an elite event offering unparalleled networking with C-level executives, VCs, and key APAC partners. It's a gateway to new funding sources and influential family offices in the APAC region, fostering significant growth opportunities and market expansion.

### Strategic audience engagement and expansion

**opportunities:** With a focus on key VCs and their limited partners, the Summit engages major players in the APAC biopharma sector. This targeted approach maximizes reach and impact, connecting attendees with new partners and investors.

### How can I join?

Please register at [www.BioCenturyEastWest.com](http://www.BioCenturyEastWest.com).

If you are unable to join in person, register instead for a Digital Pass, which includes two days of virtual one-to-one meetings.

All session recordings are available to watch for 30 days after the event.

### Are sponsorship opportunities available?

The East-West Biopharma Summit provides global visibility to Sponsors committed to innovation. Several packages are available with benefits including branding, tickets, and panelist opportunities. Please contact our team to learn more.

Exclusive packages are filling up quickly, so [contact us today!](#)

The 3rd BioCentury-BayHelix

# EAST-WEST BIOPHARMA SUMMIT: SINGAPORE

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



BioCenturyEastWest.com

SINGAPORE

MAR

4-6

2024

VIRTUAL

MAR

11-12

2024

## Can I present?

Absolutely! BioCentury is accepting nominations to join this year's Presenting Company Class. To apply, [click here](#).

## When can I start scheduling one-to-one meetings?

This year there are two days of in-person one-to-one meetings (March 5-6) followed by two days of virtual one-to-one meetings (March 11-12).

You may start scheduling meetings on Feb. 19. Before then, please make sure to update your bio and company profile in the meeting scheduler.

## How can complimentary access to BioCentury's business intelligence platform help me at the East-West Biopharma Summit?

All delegates to the conference receive complimentary access to BioCentury's business intelligence platform starting Jan. 29.

You may research pipelines, deals, and financings to determine which companies you want to meet at the East-West Biopharma Summit. There is also a Presenting Company Dashboard that helps you to review BioCentury's analysis of each company presenting at the East-West Summit.

## Are there any travel restrictions to Singapore?

Singapore is open to all transit travelers with no specific regulations or requirements. However, to ensure you have a smooth transit experience, please check the [Immigration and Checkpoints Authority website](#) on qualifying as a transit passenger and possible foreign requirements.

## How can I book my hotel accommodations?

A special room block has been secured at a discounted rate of S\$450 in effect through Feb. 24, 2024.

We encourage everyone to make your hotel accommodations as soon as possible as we expect the venue to sell out. [Click here to book your accommodations directly with the ParkRoyal Collection Marina Bay.](#)

## What if I can't attend in person?

Digital Access passes are available if you cannot attend in person. Digital passes provide full access (on-demand recordings) to all panels and presentations at the East-West Biopharma Summit. You may also schedule virtual one-to-one meetings over two days (March 11-12).


# THE BIOCENTURY SHOW

Tune in to BioCentury's twice-monthly interview series with industry leaders who are advancing the future of medicine. Available for free via webcast or podcast.

Recent guests include:

- **Paul Stoffels, M.D.**, Chairman & CEO, Galapagos
- **David Reese, M.D.**, EVP, R&D, Amgen
- **Amy Schulman**, Managing Partner, Polaris Partners
- **Najat Khan, Ph.D.**, Chief Data Science Officer, Janssen
- **Kiran Reddy, M.D.**, Senior Managing Director, Blackstone

To View Recent Episodes,  
Visit: [BioCenturyShow.com](https://www.BioCenturyShow.com)





The 3rd BioCentury-BayHelix

# EAST-WEST BIOPHARMA SUMMIT: SINGAPORE

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



BioCenturyEastWest.com

SINGAPORE

MAR

4-6

2024

VIRTUAL

MAR

11-12

2024

## EVENT ORGANIZERS

**BIOCENTURY** BioCentury gives biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; and industry-leading business intelligence, and global events. [www.biocentury.com](http://www.biocentury.com)



The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry.

Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix aspires to foster and create business opportunities, supply and nurture leaders for the community, and network and share information and experience among its members. The diverse membership base covers many of the world's top pharmaceutical and biopharmaceutical companies, leading professional services and investment firms, as well as start-up biotech companies in China and the US. BayHelix membership is by-invitation only. Over two thirds of members are C-level executives. The majority of them are cross trained in science and business as well as bilingual in Chinese and English. BayHelix has become an influential organization that connects emerging biopharmaceutical companies in China to their counterparts around the world. [www.bayhelix.org](http://www.bayhelix.org)

## INSIGHTS PARTNER



McKinsey is a global management consulting firm committed to helping organizations accelerate sustainable and inclusive growth.

We work with clients across the private, public, and social sectors to solve complex problems and create positive change for all their stakeholders. We combine bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for this generation and the next. [www.mckinsey.com](http://www.mckinsey.com)

## HELD IN



Singapore is more than its tourist attractions. It is constantly evolving, reinventing, and reimagining itself, with people who are passionate about creating new possibilities. Discover your passion in a city filled with unique adventures, diverse cultures and unexpected experiences. [www.visitsingapore.com](http://www.visitsingapore.com)

## SUPPORTED BY



Consistently ranked as Asia's Top Convention City by the International Congress and Convention Association (ICCA), Singapore is a global leader for business events. As the lead government agency for the business events sector in Singapore, the Singapore Exhibition & Convention Bureau™ (SECB) is responsible for shaping and retaining Singapore's exceptional reputation as one of the world's best business events destinations. [www.visitsingapore.com/mice](http://www.visitsingapore.com/mice)

## WELCOME RECEPTION CO-HOSTS



ClavystBio is a life sciences venture investor set up by Temasek to accelerate the commercialization of breakthrough ideas into health impact.

ClavystBio invests and partners with innovators, entrepreneurs and founders, and foster private and public partnerships to launch and grow global companies from Singapore.

Since its inception in 2022, ClavystBio has committed over US\$220m to biotech, diagnostics and digital health companies, as well as early-stage VC funds. [www.clavystbio.com](http://www.clavystbio.com)

**polarispartners** Polaris Partners has a 25-plus-year history of partnering with repeat entrepreneurs and world-class innovators who are improving the way we live and work. The multibillion-dollar firm manages specialty and diversified funds in healthcare and healthcare-adjacent technology with investments across all stages. Polaris has offices in Boston, San Francisco, New York, and Singapore. Learn more at [polarispartners.com](http://polarispartners.com).



## GALA NETWORKING DINNER HOST



Founded in 1997,  
Novotech is a global  
full-service clinical

Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase. Novotech has received numerous prestigious awards including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, and the Asia-Pacific Contract Research Organization Company of the Year Award. The Company has 34 office locations worldwide, a team of 3,000+ and has experience with over 5,000 clinical projects. Novotech's service offerings include laboratories, Phase I facilities, drug development consulting, and regulatory expertise. [www.novotech-cro.com](http://www.novotech-cro.com)

## POSTER SPOTLIGHT CO-HOST



### NSG BIOLABS

Founded with a focus on supporting  
biotech companies, NSG BioLabs offers  
state-of-the-art equipment, turnkey  
operations, preferential procurement,

the expertise of world-class teams and global networks to incubate and assist life sciences companies. NSG BioLabs, situated in the heart of Biopolis, Singapore's primary biomedical research hub, has the only BSL-2 certified co-working spaces that comprise of three fully-equipped laboratory and office facilities spread across 35,000 sq ft.

With access to a global network and a shared set of skills and experience with its strategic partners, NSG BioLabs ensures that biotech companies can execute on their cutting-edge research and development, leading to innovation of revolutionary technologies and products that translate into breakthrough biotech ventures and impact for patients.. [nsgbio.com](http://nsgbio.com)



### NSG VENTURES

NSG Ventures is a global biotech  
venture capital firm started and  
managed by scientists and founders of  
successful biotech companies with an

investment focus to back and build ear-ly-stage transformative drug discovery companies globally. The team has had experience building over 20 companies across Asia, USA, and China and these companies have raised more than US\$1BN after NSG partners' involvement.

Together with NSG BioLabs, Singapore's largest co-working laboratory and office space, the NSG Group helps companies/projects off the ground and help translate innovative technologies into breakthrough global biotech companies. [nsg.ventures](http://nsg.ventures)



Guardant Health AMEA is a wholly  
owned subsidiary of Guardant  
Health, Inc., a leading precision

oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit [guardanthealthamea.com](http://guardanthealthamea.com) and follow the company on [LinkedIn](#), [X](#) and [Facebook](#).

## NETWORKING BREAK SPONSOR



Droia invests globally in young drug  
development companies that use novel  
science and innovative approaches to bring  
promising therapies to patients. We are  
specialists, investing exclusively in therapeutics for  
oncology and genetic disease.

Our focus and our in-house team of drug development experts and biotech professionals allow us to accelerate our companies' progress by actively supporting them from company creation through clinical proof of concept. We are hands-on investors and entrepreneurs, fully dedicated to making an impact and saving patient lives. [droiaventures.com](http://droiaventures.com)



## SPONSORS

### Davis Polk

For many years, Davis Polk has been advising clients in the healthcare and life sciences – from investors to startups to the world’s largest pharmaceuticals, biotechnology and diagnostic and medical devices companies – on a full range of transactions and other legal matters. Healthcare and life sciences clients trust in our understanding of the complex issues they face in capital markets, acquisitions, divestitures, joint ventures, partnerships, strategic alliances, licensing arrangements, internal investigations and litigation. Clients appreciate that our team includes lawyers with strong biomedical backgrounds such as Ph.D.s and biomedical engineering degrees. [www.davispolk.com](http://www.davispolk.com)



Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing

transformative biologic medicines for hard-to-treat diseases. Our model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpin our passion to accelerate the journey of new drugs from concept to clinic. [www.hummingbirdbioscience.com](http://www.hummingbirdbioscience.com)



LYFE Capital is a global pioneering healthcare investment platform with \$2+Bn USD asset under management. We believe that “Healthcare has no boundaries”, and that every new choice we made has the potential to advance healthcare and solve the unmet

needs for everyone. LYFE Capital leverages our expertise and global resources to invest in and create value for healthcare companies across the globe. Our experienced team has a comprehensive understanding of the healthcare industry across the globe. Management teams value our credibility as we guide them to maximize their potential in a dynamic global market. [www.lyfecapital.com](http://www.lyfecapital.com)



Merck, a leading science and technology company, operates across life science,

healthcare and electronics. Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck generated sales of €19.7 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. [www.merckgroup.com/en](http://www.merckgroup.com/en)



MPM BioImpact is a world-leading biotechnology investment firm with more than three decades of experience creating and investing in innovative

biotechnology companies seeking to deliver transformative therapies to patients in the areas of highest unmet medical need. MPM BioImpact strives to power novel medical breakthroughs that transform patients’ lives. It invests across the biotech landscape with its early-stage venture capital funds, a public equities fund, and impact funds investing in both private and public companies. For more information visit [www.mpmcapital.com](http://www.mpmcapital.com).



Pappas Capital is a global venture capital and commercial development firm investing in next-generation life science, agriculture, and technology companies. The firm has raised more than \$800 million and has guided the launch or development of more than 100

companies through its Pappas Ventures business unit, its Specialized Fund Management unit, and its Translational Medicine initiative. Twenty-six FDA approved products have come from Pappas Capital portfolio companies. For more information, visit: [www.pappas-capital.com](http://www.pappas-capital.com)





**PUREOS** BIOVENTURES  
 Pureos Bioventures are a series of venture capital funds advised by Swiss-based Pureos Partners that invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The funds' portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, infectious disease, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact and improve patients' lives by advancing innovative treatments for devastating diseases. [www.pureosbio.com](http://www.pureosbio.com)

**Russell Reynolds ASSOCIATES**  
 Russell Reynolds Associates is a global leadership advisory firm. Our 600+ consultants in 47 offices work with public, private, and nonprofit organizations across all industries and regions. We help our clients build teams of transformational leaders who can meet today's challenges and anticipate the digital, economic, sustainability, and political trends that are reshaping the global business environment. From helping boards with their structure, culture, and effectiveness to identifying, assessing, and defining the best leadership for organizations, our teams bring their decades of expertise to help clients address their most complex leadership issues. We exist to improve the way the world is led. [www.russellreynolds.com/en/](http://www.russellreynolds.com/en/)

**SIDLEY**  
 Sidley is a global law firm with more than 150 years history and committed to providing excellent client service, fostering a culture of cooperation and mutual respect. Sidley's pioneering Global Life Sciences practice comprises an experienced team of approximately 200 lawyers across numerous legal disciplines in our offices around the world. Advising on the full scope of regulatory, compliance and enforcement, litigation and transactional matters, Sidley team offers clients a holistic legal approach that will smooth the path to navigate industry changes, technological advances, market demands and policy hurdles. [www.sidley.com/en/global/services/life-sciences/](http://www.sidley.com/en/global/services/life-sciences/)

## SUPPORTING ORGANIZATIONS



The Agency for Science, Technology and Research (A\*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organization, A\*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A\*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A\*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. [www.a-star.edu.sg](http://www.a-star.edu.sg)



flanders.bio is a dynamic, member driven organization with currently more than 360 members from Belgium and abroad. We help our members to create value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences. [flanders.bio/en](http://flanders.bio/en)



Health Campus Limburg DC is building the future of healthcare by stimulating collaborations, entrepreneurship, innovation and valorization. As such, we work towards a more qualitative healthcare system. The Campus functions as a magnet for companies, health and welfare providers, research and education. We are strongly committed to establish communities between these players. By doing so, we stimulate ties between business and governments, education, health institutions, care and welfare providers and citizens. Consequently, Health Campus Limburg DC is a hotspot to do business, to innovate and study. [healthcampus.be/en/](http://healthcampus.be/en/)



The 3rd BioCentury-BayHelix

# EAST-WEST BIOPHARMA SUMMIT: SINGAPORE

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



BioCenturyEastWest.com

SINGAPORE

MAR

4-6

2024

VIRTUAL

MAR

11-12

2024



Hong Kong Biotechnology Organization is an independent nonprofit organization (Charities exempted from tax under Section 88 of the Inland Revenue Ordinance) with the goal to promote best practice, raise awareness across the biotechnology industry while providing added value benefits to its members, whether they are students, researchers, entrepreneurs, industry bodies, public or private sector representatives.

Founded by pioneering scientists with extensive life science backgrounds and multi-cultural experience in research and development, engineering and business. Hong Kong Biotechnology Organization aims to establish and facilitate a worldwide platform for the Hong Kong biotech industry, promote awareness, encouraging and enabling international collaboration. We also provide informed opinion and technical advice to government bodies, healthcare institutions and the general public.

[www.hkbio.org.hk/index.php/en](http://www.hkbio.org.hk/index.php/en)



As the organization representing the biotechnology industry as per Article 38 of the Industry Development Act of the Korean Ministry of Trade, Industry &

Energy, the Korea Biotechnology Industry Organization strives to enhance links between the many businesses that constitute the biotechnology industry and while acting as a catalyst for further technological development and industrialization.

We hope to vitalize the activities of our individual businesses to gain greater international competitiveness so that we can contribute to further national economic development. [www.koreabio.org](http://www.koreabio.org)



Lingmed Ltd was founded in 2013 in Hong Kong. Currently we have offices in Shanghai, Beijing and Munich.

Lingmed promotes intelligence

databases and connects cross border innovations between east and west. [www.lingmed.net](http://www.lingmed.net)



The Milken Institute is a nonprofit, nonpartisan think tank focused on accelerating measurable progress on the path to a meaningful life. With a focus

on financial, physical, mental, and environmental health, we bring together the best ideas and innovative resourcing to develop blueprints for tackling some of our most critical global issues through the lens of what's pressing now and what's coming next. For more information, visit [www.milkeninstitute.org](http://www.milkeninstitute.org).



Founded in 1988, China Pharmaceutical Innovation and Research Development Association (PhIRDA) is centering on the principle of "innovation, industrialization, internationalization",

build a bridge between the government and our members. PhIRDA persists in innovation to achieve unmet clinical requirements and facilitates the industrialization of pharmaceutical innovation. Now, PhIRDA has 186 members mainly consists of pharmaceutical R&D enterprises, research institutions, clinical institutions, R&D Services companies and investment institutions focusing on pharmaceutical innovation and established 11 Specialty Committees. PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

[en.phirda.com](http://en.phirda.com)



Since its founding in 1989, the Taiwan Bio Industry Organization (Taiwan BIO) has been promoting the interests of its members from industry,

the government and academia as well as promoting the development of the biomedical industries and their contribution to Taiwan's economy and people. The more than 100 organizations and 3,000 individuals that make up Taiwan BIO membership represent the entire life sciences industry spectrum, including from the biotechnology, pharmaceutical, diagnostics, medical devices and materials, agricultural biotechnology, and nutraceuticals sectors.

[www.taiwanbio.org.tw/en](http://www.taiwanbio.org.tw/en)



REGISTER ONLINE — [WWW.BIOCENTURYEASTWEST.COM](http://WWW.BIOCENTURYEASTWEST.COM)



The BioCentury-BayHelix East-West Biopharma Summit will take place at the:

**ParkRoyal Collection Marina Bay, Singapore**

6 Raffles Boulevard  
Singapore 039594  
Telephone: +65 6845 1000

We encourage everyone to make your hotel accommodations as soon as possible as we expect the venue to sell out. [Click here to book your accommodations directly with the ParkRoyal Collection Marina Bay.](#)

A special room block has been secured at a discounted rate of S\$450 in effect through Feb. 24, 2024. Be sure to mention that you are attending the BioCentury-BayHelix East-West Biopharma Summit to receive the discounted room rate.

REGISTRATION / PRICING SCHEDULE

- **Delegate Rate** **\$1895 USD\***  
*\*early bird pricing of \$1395 is in effect through Jan. 26*
- **Qualified Presenting Company** **\$3695 USD\***  
*\*early bird pricing of \$3195 is in effect through Jan. 26*

**GROUP DISCOUNT PRICING**

Discounts are available for groups of five (5) or more from any one company. For additional information and pricing, please email: [eastwestsummithelp@biocentury.com](mailto:eastwestsummithelp@biocentury.com)

\*\*\*A special "Asia Entrepreneur" rate is available for eligible "founders" and members of the senior management team of Asia-based healthcare startups in the products and services space. This rate is subject to approval and excludes consultants, advisors, investors and multinational companies. There is a limit of two registrations per company at this rate. For more information, email: [eastwestsummithelp@biocentury.com](mailto:eastwestsummithelp@biocentury.com)

**SUMMIT WHATSAPP COMMUNITY:**

If you would like to join the Summit's WhatsApp Community Group, please [click here](#).

**EVENT DIGITAL PLATFORM**

BioCentury encourages all participants to make use of the Summit's digital event platform which may be accessed by visiting:

[biocenturyeastwest2024.meeting-mojo.com](http://biocenturyeastwest2024.meeting-mojo.com)

The platform will be open to all registered participants beginning Feb. 19, 2024, to begin scheduling 1x1 meetings. We recommend that you access the platform per email instructions that you will receive within 24-hours of registering to complete your delegate profile.

For assistance or questions regarding the digital event platform, please email:

[eastwestsummithelp@biocentury.com](mailto:eastwestsummithelp@biocentury.com)